Burrows Francis 4
4 · Kura Oncology, Inc. · Filed Dec 19, 2025
Insider Transaction Report
Form 4
Burrows Francis
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-18$4.80/sh+35,000$168,000→ 57,461 total - Sale
Common Stock
2025-12-18$9.78/sh−23,726$231,931→ 33,735 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-18−35,000→ 0 totalExercise: $4.80Exp: 2026-01-29→ Common stock (35,000 underlying)
Footnotes (4)
- [F1]Cashless exercise and sale of a portion of a stock option to cover estimated payroll tax liability.
- [F2]Includes 857 shares acquired on May 17, 2025 and 899 shares acquired on November 17, 2025 pursuant to the Issuer's Employee Stock Purchase Plan.
- [F3]This transaction was executed in multiple trades at prices ranging from $9.77 to $9.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This option is fully vested.